Cargando…

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the metabolism drug phenformin can enhance the therapeutic effect of selumetinib in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun, Nannapaneni, Sreenivas, Wang, Dongsheng, Liu, Fakeng, Wang, Xu, Jin, Rui, Liu, Xiuju, Rahman, Mohammad Aminur, Peng, Xianghong, Qian, Guoqing, Chen, Zhuo G., Wong, Kwok-Kin, Khuri, Fadlo R., Zhou, Wei, Shin, Dong M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601710/ https://www.ncbi.nlm.nih.gov/pubmed/28938614 http://dx.doi.org/10.18632/oncotarget.19779

Ejemplares similares

LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions
por: Liu, Fakeng, et al.
Publicado: (2015)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status
por: Xiao, Zhiguang, et al.
Publicado: (2014)

Phenformin as an Anticancer Agent: Challenges and Prospects
por: García Rubiño, Mª Eugenia, et al.
Publicado: (2019)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

Synergistic Anti-Cancer Effect of Phenformin and Oxamate
por: Miskimins, W. Keith, et al.
Publicado: (2014)

A Comparative Study of the Lipophilicity of Metformin and Phenformin
por: Dołowy, Małgorzata, et al.
Publicado: (2021)

The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer
por: Lee, Seon-Hyeong, et al.
Publicado: (2020)

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer
por: Kim, Jiyeon, et al.
Publicado: (2020)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Curcumin Induces Apoptosis of Upper Aerodigestive Tract Cancer Cells by Targeting Multiple Pathways
por: Amin, A. R. M. Ruhul, et al.
Publicado: (2015)

Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline
por: Wang, Dongsheng, et al.
Publicado: (2016)

Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin
por: WANG, STEPHANIE S., et al.
Publicado: (2014)

Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma
por: Jiang, Wei, et al.
Publicado: (2016)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
por: Kim, Jiyeon, et al.
Publicado: (2017)

Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer
por: Lee, Hyunmin, et al.
Publicado: (2022)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
por: Khuri, Fadlo R.
Publicado: (2021)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
por: Bhatt, Vrushank, et al.
Publicado: (2023)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

Phenformin Down-Regulates c-Myc Expression to Suppress the Expression of Pro-Inflammatory Cytokines in Keratinocytes
por: Liu, Guanyi, et al.
Publicado: (2022)

2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells
por: Sun, Linlin, et al.
Publicado: (2016)

Blockade of P-Glycoprotein Decreased the Disposition of Phenformin and Increased Plasma Lactate Level
por: Choi, Min-Koo, et al.
Publicado: (2016)

Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma
por: Petrachi, Tiziana, et al.
Publicado: (2016)

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes
por: Coperchini, Francesca, et al.
Publicado: (2019)

Effects of metformin and phenformin on apoptosis and epithelial‐mesenchymal transition in chemoresistant rectal cancer
por: Park, Ji‐Hye, et al.
Publicado: (2019)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth in vivo in head and neck cancer models
por: Amin, A.R.M. Ruhul, et al.
Publicado: (2021)

The antitumor properties of metformin and phenformin reflect their ability to inhibit the actions of differentiated embryo chondrocyte 1
por: Kuo, Chun-Lin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ca4akdkra8pkve83kfc87v2jgd